Supplementary material to article by A. Costanzo et al. "Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study"




Fig. S2. Patient-level Psoriasis Area and Severity Index (PASI) status overtime (week 16 to 48) in patients who were PASI 90 responders/non-responders at week 16. Composite endpoint: DLQI: Dermatology Life Quality Index; and PASI. In order to take into account patient's point of view (patient-reported outcome) with clinical assessment, a new composite index was drawn as follow: Super-responder: all patients with PASI 90 or DLQI 0 or 1. The percentage of super-responders was lower, while the responder percentage were slightly greater than the proportion of patients in the simple P90R (week 16: 61.2 and 86.6% vs 82.4%, respectively). The percentages proportionally increased at week 24 and remained stable at week 48 (Fig. S4).